Lumacaftor/ivacaftor-associated health stabilisation in adults with severe cystic fibrosis

INTRODUCTION: Lumacaftor/ivacaftor (LUM/IVA) has been shown to improve clinical outcomes in cystic fibrosis (CF) patients homozygous for Phe508del with forced expiratory volume in 1 s (FEV(1)) % pred >40%. We assessed the clinical utility of LUM/IVA in all eligible adult CF patients with FEV(1) %...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:ERJ Open Res
Glavni autori: King, Susannah J., Keating, Dominic, Williams, Elyssa, Paul, Eldho, Borg, Brigitte M., Finlayson, Felicity, Button, Brenda M., Wilson, John W., Kotsimbos, Tom
Format: Artigo
Jezik:Inglês
Izdano: European Respiratory Society 2021
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7861032/
https://ncbi.nlm.nih.gov/pubmed/33569502
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/23120541.00203-2020
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items